Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jessica Swarr

Physician Assistant Dayton, OH Physician Assistant

NPI 1548498652 CMS profile 10880024

1 Childrens Plz, Advance Practice Ent, Dayton, OH 45404

Open in the dashboard

General payments

$9,955

554 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Swarr of Dayton, OH is reported in the CMS Open Payments database as having received $9,955 across 554 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,376 124
2024 General $2,566 134
2023 General $2,312 122
2022 General $1,270 76
2021 General $1,431 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Swarr
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jessica Swarr were reported at $2,376. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jessica Swarr Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,431 $132 $37–$438 $132
2022 $1,270 $155 $48–$522 $149
2023 $2,312 $167 $52–$557 $160
2024 $2,566 $178 $55–$600 $164
2025 $2,376 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,253 92 payments
  2. Alkermes, Inc. $1,211 56 payments
  3. Lundbeck LLC $1,113 66 payments
  4. ITI, Inc. $1,086 65 payments
  5. Teva Pharmaceuticals USA, Inc. $974 48 payments
  6. Otsuka America Pharmaceutical, Inc. $901 53 payments
  7. Corium, Inc. $512 28 payments
  8. Janssen Pharmaceuticals, Inc $511 23 payments
  9. Neurocrine Biosciences, Inc. $503 28 payments
  10. Vanda Pharmaceuticals Inc. $390 16 payments
  11. Other $1,501 79 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,838 551 payments
  2. Education $117 3 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $1,088 80 payments
  2. LYBALVI $951 44 payments
  3. ARISTADA Cns $893 46 payments
  4. ARISTADA Cns $893 46 payments
  5. ABILIFY MAINTENA $785 41 payments
  6. CAPLYTA $727 45 payments
  7. ARISTADA Cns $697 32 payments
  8. ARISTADA Cns $697 32 payments
  9. Austedo XR $581 30 payments
  10. Azstarys $512 28 payments
  11. Other $6,705 350 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,768

Median for Physician Assistant: 241

Drug cost

$295,097

Median for Physician Assistant: $4,110

Branded share of claims

24.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 17 $140,945
Rexulti Brexpiprazole Brand 27 $45,414
Vraylar Cariprazine Hcl Brand 24 $33,404
Caplyta Lumateperone Tosylate Brand 16 $32,202
Aripiprazole Generic 252 $17,803
Olanzapine Generic 117 $2,834
Bupropion Xl Bupropion Hcl Brand 128 $2,252
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 38 $2,047
Fluvoxamine Maleate Generic 29 $1,977
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 42 $1,677

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$39,013

Medicare's payments for the services billed

Medicare patients

72

Average age 65

Services billed

739

37 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 68%
Arthritis 49%
Diabetes 28%
Ischemic heart disease 28%
Chronic kidney disease 24%
Osteoporosis 18%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Azstarys
  • Corium, Inc. $328
$328 — —
VRAYLAR
  • AbbVie, Inc. $325
$325 24 —
CAPLYTA
  • ITI, Inc. $304
$304 16 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $117
  • Lundbeck LLC $68
$186 27 —
ABILIFY MAINTENA
  • Lundbeck LLC $169
  • Otsuka America Pharmaceutical, Inc. $13
$182 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

554 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record